このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Immunovia マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Philipp Mathieu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.009%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	5.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Philipp Mathieu

less than a year

在職期間

Mr. Philipp Mathieu serves as Chief Executive Officer and President at Immunovia AB (publ) since June 02, 2022. Mr. Mathieu served as an Acting CEO & President of Immunovia AB (publ) since January 20, 2022...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Philipp Mathieu	CEO & President	less than a year	データなし	0.0093% SEK 51.4k
Karin Liwendahl	Chief Financial Officer	less than a year	データなし	データなし
Jeff Borcherding	Chief Executive Officer of US	less than a year	データなし	データなし

1.0yrs

平均在職期間

経験豊富な経営陣: IMMNOSの経営陣は経験豊富とはみなされません ( 1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Carl Arne Borrebaeck	Independent Chairman of the Board	16yrs	kr580.00k	7.56% SEK 41.7m
Hans Johansson	Independent Director	6yrs	kr288.00k	0.14% SEK 761.7k
Margaret Tempero	Member of Scientific Advisory Board	6.6yrs	データなし	データなし
Philipp Sixt Von Hugo	Independent Director	less than a year	データなし	データなし
Diane Simeone	Member of Scientific Advisory Board	6.5yrs	データなし	データなし
Stephen Pereira	Member of Scientific Advisory Board	5.5yrs	データなし	データなし
Eric Krafft	Independent Director	less than a year	データなし	データなし
Peter Andersen	Independent Director	2.7yrs	kr268.00k	0.052% SEK 286.0k
Martin Moller	Director	1.7yrs	kr160.00k	0.0047% SEK 25.8k

5.5yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: IMMNOSの取締役会は経験豊富であると考えられます ( 5.5年の平均在任期間)。

Immunovia マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently bought kr186k worth of stock

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Revenue in line with expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Immunovia AB Announces Results from Study in Their Development Pipeline

New 90-day low: kr111

Director recently bought kr144k worth of stock

New 90-day low: kr122

Immunovia AB (Publ) Announces Appointment of Members of Nomination Committee

Immunovia AB (publ) Announces Management Changes

Immunovia AB (Publ) Announces Completion of Analysis from the Immray Pancan-D Verification Study

Immunovia Announces Positive Results from the Immray Pancan-D Verification Study

Immunovia AB (Publ) Appoints Mats Grahn as New Member of the Board of Directors

Immunovia Announces CEO Transition, Effective November 1, 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14